152 related articles for article (PubMed ID: 37399615)
1. Design, synthesis and biological evaluation of novel modified dual-target shikonin derivatives for colorectal cancer treatment.
Ma Y; Lai X; Wen Z; Zhou Z; Yang M; Chen Q; Wang X; Mei F; Yang L; Yin T; Sun S; Lu G; Qi J; Lin H; Han H; Yang Y
Bioorg Chem; 2023 Oct; 139():106703. PubMed ID: 37399615
[TBL] [Abstract][Full Text] [Related]
2. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism.
Lin H; Han H; Yang M; Wen Z; Chen Q; Ma Y; Wang X; Wang C; Yin T; Wang X; Lu G; Chen H; Qi J; Yang Y
Eur J Med Chem; 2023 Mar; 249():115166. PubMed ID: 36731272
[TBL] [Abstract][Full Text] [Related]
3. Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1/PDHC axis.
Chen Q; Han H; Lin F; Yang L; Feng L; Lai X; Wen Z; Yang M; Wang C; Ma Y; Yin T; Lu G; Lin H; Qi J; Yang Y
Life Sci; 2022 Dec; 310():121077. PubMed ID: 36244412
[TBL] [Abstract][Full Text] [Related]
4. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
5. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
6. Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells.
Cao Y; Lin Y; Wang D; Pan D; Zhang Y; Jin Y; Zheng C
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1081-1086. PubMed ID: 30155759
[TBL] [Abstract][Full Text] [Related]
7. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells.
Zhou CF; Li XB; Sun H; Zhang B; Han YS; Jiang Y; Zhuang QL; Fang J; Wu GH
IUBMB Life; 2012 Sep; 64(9):775-82. PubMed ID: 22807066
[TBL] [Abstract][Full Text] [Related]
9. Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer.
Kitayama K; Yashiro M; Morisaki T; Miki Y; Okuno T; Kinoshita H; Fukuoka T; Kasashima H; Masuda G; Hasegawa T; Sakurai K; Kubo N; Hirakawa K; Ohira M
Cancer Sci; 2017 Dec; 108(12):2462-2469. PubMed ID: 29032577
[TBL] [Abstract][Full Text] [Related]
10. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation.
Zhang Q; Liu Q; Zheng S; Liu T; Yang L; Han X; Lu X
J Cancer; 2021; 12(16):4830-4840. PubMed ID: 34234853
[No Abstract] [Full Text] [Related]
11. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis.
Dai ZQ; Gao F; Zhang ZJ; Lu MJ; Luo YJ; Zhang T; Shang BX; Gu YH; Zeng Q; Gao S; Guo ZQ; Xu B; Lei HM
Phytomedicine; 2023 Aug; 117():154912. PubMed ID: 37295023
[TBL] [Abstract][Full Text] [Related]
12. Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2.
Liu T; Li S; Wu L; Yu Q; Li J; Feng J; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
J Hepatocell Carcinoma; 2020; 7():19-31. PubMed ID: 32110554
[TBL] [Abstract][Full Text] [Related]
13. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
Li W; Liu J; Zhao Y
Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
[TBL] [Abstract][Full Text] [Related]
14. Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis.
Yu S; Zang W; Qiu Y; Liao L; Zheng X
Oncogene; 2022 Jan; 41(1):46-56. PubMed ID: 34671086
[TBL] [Abstract][Full Text] [Related]
15. HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells.
Huang L; Yu Z; Zhang T; Zhao X; Huang G
PLoS One; 2014; 9(3):e92949. PubMed ID: 24658033
[TBL] [Abstract][Full Text] [Related]
16. The interaction between apigenin and PKM2 restrains progression of colorectal cancer.
Shi J; Ji X; Shan S; Zhao M; Bi C; Li Z
J Nutr Biochem; 2023 Nov; 121():109430. PubMed ID: 37597817
[TBL] [Abstract][Full Text] [Related]
17. Tumor M2-PK: A novel urine marker of bladder cancer.
Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
[TBL] [Abstract][Full Text] [Related]
18. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
19. miR-142-3p Modulates Cell Invasion and Migration via PKM2-Mediated Aerobic Glycolysis in Colorectal Cancer.
Ren J; Li W; Pan G; Huang F; Yang J; Zhang H; Zhou R; Xu N
Anal Cell Pathol (Amst); 2021; 2021():9927720. PubMed ID: 34336555
[TBL] [Abstract][Full Text] [Related]
20. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery.
Long L; Xiong W; Lin F; Hou J; Chen G; Peng T; He Y; Wang R; Xu Q; Huang Y
J Exp Clin Cancer Res; 2023 May; 42(1):117. PubMed ID: 37161591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
